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The possible link between infection/inflammation/immune activation and a cancer patient’s
outcome from both a causative and outcome point of view has long been postulated.
Substantial progress in the understanding of tumor-associated antigens/epitopes, immune
cellular subpopulations, cytokine pathways/expression, the tumor microenvironment, and
the balance between tumor-immune suppression and stimulation have been made over the
past decade.This knowledge has heralded a new era of tumor immunotherapy utilizing vac-
cines, immune checkpoint inhibition, and oncolytic viruses. Despite significant progress in
the molecular era now with targeted therapeutics such as EGFR tyrosine kinase inhibitors
and ALK fusion protein inhibitors that have significantly improved the outcome of these
specific lung cancer subpopulations, the overall 5 year survival for all non-small cell lung
cancer (NSCLC) is still <20%. Unlike malignancies such as malignant melanoma, renal cell
carcinoma, and neuroblastoma given their documented spontaneous remission rates lung
cancer historically has been felt to be resistant to immune approaches likely related to an
immunosuppressive tumor microenvironment and/or lack of immune recognition. Defin-
ing responding populations, understanding the mechanism(s) underlying durable immune
responses, and the role of chemotherapy, radiation, oncolytic viruses, and other tumor
disrupting agents in augmenting immune responses have led to improved optimization
of immune therapeutic strategies. The purpose of this review is to focus on the recent
advances in lung immunotherapy with an emphasis on recent clinical trials in the last
5 years in NSCLC.
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INTRODUCTION
Lung cancer is the number one cause of cancer mortality globally
and has an estimated incidence of 1.3 million new cases every year
(1). Approximately 80–85% of the newly diagnosed cases of lung
cancer are non-small cell lung cancer (NSCLC) (adenocarcinoma,
squamous carcinoma, and large cell carcinoma) and 15–20% small
cell lung carcinoma. In the majority of cases, patients present with
unresectable and/or non-curable disease (2). Locally advanced,
good performance status NSCLC patients may be offered concur-
rent chemotherapy, radical radiotherapy, and/or surgery, with a
resultant 8-month progression-free survival rate and<15% 5-year
survival (3). Patients diagnosed with metastatic disease newer
cytotoxic chemotherapies such as pemetrexed [17-month median
overall survival (OS)] and treatment with molecularly targeted
therapeutics for adenocarcinomas, such as next generation small
molecules targeting the EGFR (24 months median OS) and ALK
inhibitors (20 months median OS), the survival rate for advanced
disease has improved only marginally (4–6). In the last decade,
there has been a better understanding on how cancer interacts
with the immune cells and the ways that the cancer have devel-
oped to evade the immune system, resulting in a new era of
cancer immunotherapy protocols, which may aid in overcoming
the limitations of conventional therapeutic strategies (7).
Two such immunotherapeutic strategies in NSCLC are cur-
rently in clinical trials that involve increasing tumor immuno-
genicity by using cancer vaccines to augment tumor-immune
recognition and overcoming tumor immunosuppression by using
immune checkpoint inhibitors (Figure 1).
CANCER VACCINES
Cancer vaccines are biologically active antigenic preparations that
ideally educate the immune system about an existing cancer (8, 9).
For a cancer vaccine to be effective, it should target an antigen spe-
cific to the cancer cell, i.e., tumor-associated antigens (TAA), which
are frequently elevated in the circulation of cancer patients (10).
Vaccines have historically been (glyco) peptides, recombinant pro-
teins, or whole cancer cell preparations (that have been rendered
replication incompetent); however, since antigenic peptides sub-
optimally activate antigen presenting cells (APCs), vaccines are
usually augmented by an immunoadjuvant or immunostimulant
in the form of inactive pathogen or other non-specific immune
stimulant. Cancer vaccines are taken up APCs, which later migrate
to the nearest draining lymph node and consequently activate T-
and B-lymphocytes. Specific T-cells will differentiate and expand
to become tumor specific effector cells that will home to the tumor
microenvironment which hosts the original antigens (11). It is of
interest to speculate whether immune targeted therapeutics will
be more effective if the tumor is initially disrupted by cytotoxic
chemotherapy and/or radiation or some other cellular disrupting
strategy, i.e., radiofrequency ablation/cryotherapy/oncolytic virus
in order to augment antigen/epitope exposure to the immune
system. There are numerous types of cancer vaccines that have
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FIGURE 1 | Schematic diagram of immunotherapeutic strategies in NSCLC.
been tested in clinical trials involving NSCLC patients as discussed
below.
BELAGENPUMATUCEL-L
Belagenpumatucel-L (Lucanix®) (NovaRx Corporation, San
Diego, CA, USA) is an allogeneic tumor cell vaccine prepared
from four irradiated human NSCLC cell lines SK-LU-1 (adeno-
carcinoma), NCI-H 460 (large cell carcinoma), NCI-H 520, and
Rh 2 [squamous cell carcinoma, transfected with a transgene plas-
mid containing an antisense construct against the TGF-β2 gene
(12)]. Elevated levels of TGF-β are frequently associated with
immunosuppression in cancer through antagonizing the function
of natural killer cells (NK) and dendritic cells (DC) (13). Moreover,
the prognosis of NSCLC patients has been found to be inversely
correlated with the level of TGF-β (14).
In the first of two phase II studies using the intradermal Lucanix
vaccine involving stage II–IV NSCLC patients with low-tumor
burden who had completed or refused conventional therapy toler-
ated the treatment well. Those patients with advanced disease who
received higher doses (N = 41,>2.5× 107 cells/intradermal injec-
tion monthly) had a significant improved 2-year survival com-
pared to the low-dose cohort [(N = 20,<2.5× 107 cells/injection)
(47 versus 18%) (p= 0.0069)] (13). A second trial confined to
pretreated stage IV NSCLC patients had an OS of 19 months (14).
Interestingly, in this trial, the vaccine elicited both a cell medi-
ated and a humoral immune response in the form of high level of
cytotoxic cytokines and increased IgG and IgM titers.
The phase III survival, tumor free, overall, and progression-
free (STOP) clinical trial, involving advanced NSCLC patients,
pretreated with a first-line platinum-based chemotherapy,
treated similarly (2.5× 107 cells/intradermal monthly injection)
presented at the European Cancer Congress 2013 revealed a
median OS of 20.3 and 17.8 months in Lucanix and placebo
groups, respectively [hazard ratio (HR) 0.94; p= 0.594]. Although
the OS was numerically longer STOP trial did not meet the pri-
mary endpoint. On the other hand, this analysis demonstrated
improved OS in two subgroups, the non-adenocarcinoma and
the stage IIIB/IV patients who started the vaccine therapy within
12 weeks of the finishing the initial chemotherapy.
TG4010
The TG4010 vaccine is a suspension of recombinant modified vac-
cinia virus of Ankara (MVA strain) vector vaccine that expresses
the TAA MUC1 and interleukin (IL)-2 (15). MUC1 is a trans-
membrane glycoprotein, which is normally expressed on normal
duct epithelia, such as those lining the breast, prostate, lung,
stomach, bladder epithelium, and sweat glands (16). Its normal
function is related to mucin formation; however, in cancer its
function is altered, due to excessive glycosylation, which con-
tributes to its immunogenicity. High-MUC1 expression correlates
with invasiveness and a poor prognosis for lung cancer (17).
Furthermore, MUC1 overexpression activates phosphatidylinos-
itol 3-kinase (PI3K) and the AKT pathways and resultant cell
proliferation (18).
The initial randomized phase II study that included 65
patients with stage III/V NSCLC showed that TG4010 (108
plaque forming units injected subcutaneously weekly for 6 weeks
then every 3 weeks) in combination with chemotherapy (cis-
platin/vinorelbine) (N = 44) versus TG4010 monotherapy until
progression followed by the addition of chemotherapy (N = 21)
was generally well tolerated. The combination group had a
response rate of 30 versus 0% in the TG4010 group, however, a
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numerically inferior median and 1-year survival rate (19). Despite
this a larger multicenter, open-label randomized phase IIB trial
was conducted (20). This study enrolled 148 IIIB (pleural effu-
sion)/IV patients with a 1:1 randomization to the combination
therapy of TG4010 plus chemotherapy versus chemotherapy (cis-
platin and gemcitabine) alone. The primary end point of the study
was achieved with a resultant 6-month progressive free survival
(PFS) of the combined group of 43% (95% CI 33.4–53.5) ver-
sus 35% (95%CI 25.9–45.3) in the control group. Notably, the
objective response rate and median OS of responding patients
was higher in the TG4010 group than in the chemotherapy alone
group: 41.9 versus 28.4% and 23.3 versus 12.5 months, respectively.
In this study, patients who presented with high levels for activation
marker for NK cells (CD16+CD56+CD69+) at the baseline levels
had the worst outcome. Thus, the presences of these markers may
act as potential biomarker for the safety and efficiency of TG4010.
Of note, FDA approved a phase III study on TG4010 in a subpop-
ulation of patients with advanced NSCLC and normal levels of
activated NK cells.
There is an ongoing Phase IIB/III randomized, double-blinded,
placebo-controlled study comparing first-line therapy with or
without TG4010 immunotherapy product in patients with stage
IV NSCLC (TIME trial) currently accruing patients in Europe and
the US.
BLP25
BLP25 (Tecemotide®) (also known as L-BLP25 and Stimuvax)
is a liposomal vaccine, which is formed from the immunoad-
juvant monophosphoryl lipid A, and three lipid components
(cholesterol, dimyristoyl phosphatidylglycerol, and dipalmitoyl
phosphatidylcholine) (21) that harbors a 25 amino acid syn-
thetic immunodominant core peptide of MUC1 TAA that has
been shown to elicit a strong T-cell immune response both
in transgenic murine lung cancer models and in patients (21–
23). Recently, using a MUC1.Tg lung cancer mouse model, it
was demonstrated that pre-administration of cyclophosphamide
(CPA) with BLP25 increases the levels of the immune stimulating
T-helper 1 (Th1) response [IL-2 and interferon gamma (IFN-
γ)], as well as other inflammatory chemokines such as IP-10,
MIG, KC, MCP-1, and MIP-1α (22), may enhance immunother-
apy by boosting both cellular and humoral mediated antitumor
immune responses for the vaccine by inhibiting regulatory T
(Treg) cells (24–26).
A phase IIB clinical trial was conducted involving 171 stage IIIB
and IV NSCLC patients with stable or better response to first-line
chemotherapy or chemo-radiotherapy with a primary objective
of OS and toxicity (21). The secondary endpoints investigated the
health related quality of life (QQL) and immune response elicited
by the vaccine. Patients were randomized to receive BLP25 plus
best supportive care (BSC) versus BSC only. BLP25 or placebo
was given subcutaneously weekly× 8 then 6 weekly until progres-
sion or significant toxicity. All patients in the BLP25 arm received
a low dose of CPA prior vaccination. Although, the median sur-
vival time was 4.2 months longer in the treatment arm, this result
was not statistically significant [17.2 versus 13 months, HR 0.74
(0.53–1.0)]. In addition, the 3-year OS was higher in BLP25
plus BSC group than the BSC group (31 versus 17%, p= 0.035).
Interestingly, a 17.3-month improved survival as well as improved
QQL was observed in those patients with stratified stage IIIB
locoregional disease who received the BLP25 plus BSC [30.6 versus
13.3 months, HR 0.54 (0.3–0.99)]. The 3-year OS in this subgroup
was also numerically higher in BLP25 plus BSC group than the
BSC group (49 versus 27%, p= 0.07). Whether or not patients
with a lower tumor burden, no metastasis and perhaps patients
that receive multimodality treatment may benefit preferentially
from this vaccine is unclear. Evidence of T-cell mediated immu-
nity was only detected in only approximately 20% of the patients
in the BLP25 arm, thought in part to be due technical prob-
lems related to decrease lymphocyte viability during collection
and transportation.
On the strength of the above findings, two phase III trials
were conducted. The stimulating targeted antigenic responses
to NSCLC (START) clinical trial an international, randomized,
double-blinded trial evaluated BLP25 as a maintenance therapy
in stage III NSCLC patients with stable disease or better response
after chemotherapy (27). The study was initiated in 2007 with
recruitment of 1513 patients from 264 trial centers in 33 countries
worldwide. Unfortunately, as a result of fatal encephalitis reported
in a patient with malignant melanoma that was treated with
BLP25 on an exploratory trial, the Food and Drug Administration
agency placed a hold on the BLP25 clinical trials for approximately
135 days. This hold was suggested to have a negative impact on
trial objectives as it resulted in a total of 274 patients from the
BLP25 and placebo groups to be excluded from the study. The
median OS and the 1–3 year survival rate between the two groups
(BLP25 and placebo) were not statistically significant. Interest-
ingly, the median OS for BLP25 compared to placebo arms in the
concurrent chemo-radiotherapy subgroup was statistically signif-
icant [30.8 versus 20.6 months (HR 0.78, 0.64–0.95)]; however,
no differences were noted in patients who had received sequen-
tial chemo-radiotherapy. The second phase II trial the INSPIRE
trial (BLP25/Stimuvax trial In Asian NSCLC Patients stimulating
Immune Response) (NCT01015443) is a double-blinded random-
ized 2:1 (BLP25: placebo) trial and is still ongoing (28). The study
will target 420 patients with unrespectable stage III NSCLC from
40 trial sites in Asia (China, Hong Kong, Singapore, South Korea,
and Taiwan) excluding Japan.
MAGE-A3
Human melanoma antigen (MAGE)-A, -B, and -C are a fam-
ily of genes normally expressed during embryogenesis and are
also expressed in the immunoprivileged human tissues sites (29).
Although, these genes are expressed in testicular germ cells and pla-
centa trophoblasts, the antigens are not presented to the immune
cells because of the lack of class I human leukocyte antigen
molecules (HLA) (30, 31). For that reason, expression of these
antigens on tumor cells that express class I HLA to the immune
cells are likely immunogenic. Tumor cells such as melanoma,
sarcoma, bladder, liver, esophageal, and lung cancers overexpress
these antigens and hence considered tumor-associated antigens
(32). MAGE-A3, a subtype of this family of genes, is differen-
tially expressed in early stage (35%) and advanced stage (55%)
lung cancer and hence it is theoretically a good target for tumor
immunotherapy (33).
www.frontiersin.org October 2014 | Volume 4 | Article 288 | 3
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mostafa and Morris Taking out clinical trials
The MAGE-A3 vaccine (GlaxoSmithKline) is composed of
the recombinant full-length protein MAGE-A3, Haemophilus
influenza protein D that acts as an immune adjuvant and an
immunostimulant AS02B or AS15 (34). The advantage of using
the full protein is the production of several immunodominant
epitopes that can be presented in the context of HLA class I and II
and consequently activate both CD4 and CD8 T-cells. The broad
array of T-cell responses can be in the form of Th response, cyto-
toxic T-cells (CTL), Th17 cells, and memory T-cells that result in
immune effector antitumor immune responses (38). Recent find-
ings indicate a beneficial role for MAGE-A3 vaccine in triggering
the immune system including a study, which reported 84 genes as
a gene expression signature (GS) in melanoma and NSCLC (35).
These genes are involved in IFN-γ pathways, adaptive immunity,
and specific chemokines that are responsible for T-cell activation
and homing. When the MAGE-A3 vaccine was used with these
GS-positive NSCLC patients, the disease free interval was in favor
of the MAGE-A3 group compared to placebo group. In addition,
no effect of the MAGE-A3 vaccine on the OS was noticed when
GS was not taking into account, indicating that GS may act as an
immune biomarker.
In order to evaluate the clinical benefit of the MAGE-A3
vaccine as an adjuvant treatment in postoperative lung can-
cer, 182 patients with completely resected MAGE-A3 positive
stage IB/II NSCLC were enrolled into randomized (2:1 ratio),
double-blinded, placebo-controlled phase II trial (36). Although
all patients who received MAGE-A3 developed anti-MAGE-A3
immunoglobulin G antibodies, suggesting that vaccine triggered
the immune response, no statistically significant difference were
observed between the two groups with regards DFI, DFS, and OS.
After applying forest plot analysis for HR (95% CI) to stratifica-
tion factors, tumor stage, histology, and resection technique, all
estimated values favored MAGE-A3 over placebo. Limited sam-
ple size and lack of chemotherapy as an adjuvant therapy were
the main limitation of this study, which was later modified in the
following phase III trial.
MAGRIT (MAGE-A3 as Adjuvant Non-Small Cell LunG
CanceR ImmunoTherapy) was the largest ever phase III lung
cancer adjuvant trial that aimed in determining the efficiency
of MAGE-A3 vaccine as an adjuvant therapy following tumor
resection in MAGE-A3 positive stage IB, II, and IIIA NSCLC
(37). The other objectives were to study the toxicity. The study
started in 2007 and recruited 2270 patient from 400 trial centers
in 33 countries. Patients were randomly selected in 2:1 ratio and
included patients who undergone surgery with or without adju-
vant chemotherapy. Unfortunately, GlaxoSmithKline announced
in April 2014 that MAGRIT study was to be discontinued due to
failure to meet its primary objective, with no significant difference
noted in DFS between MAGE-A3 and placebo group. Subgroup
analyses are currently underway to see if there was a subpopulation
that may have had more benefit.
OTHER
There are many other vaccination strategies currently in preclinical
or early human clinical trial testing. One of these utilizes the anti-
gen PRAME (preferentially expressed in melanoma) involved in
retinoic acid receptor repression although expressed in low levels
in many normal tissues and is overexpressed in both melanoma
and NSCLC and therefore a vaccination target. A dose escalation
study of recombinant PRAME protein in a liposomal formulation
containing the immune adjuvant AS15 (GSK2302032) is currently
recruiting patients with resected early stage NSCLC. Other vac-
cines directed at epidermal growth factor ligand in combination
with cyclophosphamide (CIMAvax) and cell therapy and oncolytic
viral strategies containing constructs expressing various antigens
or immune stimulating cytokines (GM-CSF) are currently being
investigated.
IMMUNE CHECKPOINT REGULATORS
Initiation of adaptive immunity is a complex multifaceted mech-
anism that takes place between APCs and T-cells. A homeostatic
balance between stimulatory and inhibitory signals is required
to prevent over/under stimulation of T-cells, which may result
in autoimmunity or immunosuppression sequelae, respectively
(38, 39). APCs take up foreign antigen, process it, and express
the antigen on its surface in the context of class II HLA, which
then engages the T-cell receptor on the surface of T-cells. A second
signal through the costimulatory molecules facilitated by bind-
ing of CD28 on T-cell surface by CD86 (B7-2) on APCs. As a
result of these specific interactions, T-cells are activated and secrete
cytokines (third signal) such as IL-2 stimulating T-cell clonal pro-
liferation. In order to prevent autoimmunity, T-cell proliferation is
negatively regulated by cytotoxic T-lymphocyte antigen 4 (CTLA-
4), which is expressed on the surface of activated T-cells. CTLA-4 is
a member of immunoglobulin superfamily and binds to B7-2 with
much higher affinity than CD28 and therefore when expressed
the T-cell response is down regulated. Furthermore, CTLA-4 is
expressed by the Tregs thereby enabling them to suppress the effec-
tor T-cells. CTLA-4 regulation takes place in the early activation
phase of immune induction occurring in the regional lymph nodes
at the level of the APC and unprimed T-cell interaction.
Another significant immune check point regulator molecule
that has been extensively studied is the programed death-1 (PD-1)
molecule (40). PD-1 is expressed on the surface of activated T-cells
and its active ligand [PD-L (B7-H1)] is expressed on macrophages
and can be also actively induced in endothelial, epithelial, and
tumor cells. PD-1 can also binds to PDL-2, which is expressed
mainly on APC and some tumor cells. Unlike CTLA-4 negative
regulation PD-1/PDL-1 takes place in the peripheral tissue/tumor
during the effector phase of T-cell activation. Both CTLA-4 and
PD-1 have been targeted by inhibitory antibodies as an adjuvant
therapy in cancer in attempt to enhance T-cell activation and
tumor immunity (41).
IPILIMUMAB
Ipilimumab also known as MDX-010 and MDX-101 (Yervoy,
Bristol-Myers Squibb) is a human monoclonal antibody directed
against CTLA-4 molecule. Ipilimumab blocks the interaction of
CTLA-4 with its ligand B7-2, resulting in T-cell activation, prolif-
eration, induction of cytotoxic cytokines, and tumor suppression
(42). Phase I/II trials have identified the safety and tolerabil-
ity of CTLA-4 inhibition in several cancers that include the
significant risk of colitis and, hepatotoxicity, skin rash, and
hypophysitis/hypopituitarism (43). Moreover, they significantly
improved OS in patients with malignant melanoma in phase III
trials (44).
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Two concurrent randomized phase II trials used ipilimumab
in combination with chemotherapy (carboplatin/paclitaxel) for
extensive stage small cell lung cancer (n= 130) and advanced stage
NSCLC (n= 204) (45, 46). The primary endpoint of these studies
was immune-related progression-free survival (irPFS). Secondary
endpoints included PFS, best overall response rate (BORR),
immune-related BORR (irBORR), OS, and safety. Patients were
randomized to three groups (1:1:1), placebo/chemotherapy alone
for up to six cycles, concurrent ipilimumab plus chemother-
apy (four doses of ipilimumab/chemotherapy followed by two
doses of placebo/chemotherapy) or phased ipilimumab (two
doses of placebo/chemotherapy followed by four cycles of ipili-
mumab/chemotherapy). Phased ipilimumab, but not concurrent
ipilimumab group, significantly improved irPFS in both the SCLC
and NSCLC studies (HR 0.64 p= 0.03; HR 0.72, p= 0.05, respec-
tively) and PFS in the NSCLC study (HR 0.69, p= 0.02) compared
to patients who received placebo/chemotherapy alone. This find-
ing was felt to be explained by chemotherapy induced tumor
antigen release by chemotherapy trigger T-cell activation thus
augmenting the effects of the immune checkpoint blockade (47).
Of note, the improved irPFS in the phased ipilimumab NSCLC
study was mainly confined to patients who had squamous cell
histology. This is consistent with an increase T-cell infiltration
found in squamous NSCLC (48). Further, an interesting case
report of a patient with metastatic systemic treatment refractory
NSCLC who was treated with palliative concurrent radiother-
apy and ipilimumab that was associated with both a local and
distant tumor complete response. A post-treatment increase in
tumor-infiltrating cytotoxic lymphocytes, tumor regression, and
normalization of tumor markers was observed. One year after
treatment the patient was without evidence of disease based on
PET/CT imaging (52). Two phase III trials NCT01450761 (ED-
SCLC, etoposide/platinum, N = 1125, first data November 2015)
and NCT01285609 (advanced NSCLC, carboplatin/paclitaxel,
N = 920, first data October 2015) are still recruiting participants
comparing ipilimumab plus chemotherapy versus chemotherapy
alone in patients recently diagnosed ED-SCLC and squamous
NSCLC, respectively.
NIVOLUMAB AND MK-3475
Nivolumab (Bristol-Myers Squibb) and MK-3475 (Merck) are
fully human antibodies that inhibit PD-1 receptors expressed on
activated T-cells (49). Both block the binding of PDL-1/2 with PD-
1 on surface of activated T-cells, and consequently increases T-cell
activation by removing the inhibitory signaling of PD-1 (50). As
PDL-1 is only expressed on selected tumor cells, the adverse effect
of the drug is expected to be less than ipilimumab. A Phase I
trial (N = 129) for nivolumab at three different doses (1, 5, and
10 mg/kg every 2 week) in NSCLC treatment refractory patients
reported an overall 2 years survival rate 24% with median OS of
9.9 months with minimal toxicity (51). Interestingly, the 3 mg/kg
group did the best with a BORR of 24.3% and a duration of
response of 74 weeks and a median OS of 14.9 months. A Phase
III trial involving nivolumab compared to docetaxel in second
line and beyond is ongoing (NCT01673867) and will recruit 582
patients with metastatic/recurrent non-squamous NSCLC with a
primary objective of OS in PD-1 inhibitor versus chemotherapy
groups. The secondary objectives will determine PFS and disease
related symptom progression, and evaluation of clinical benefit of
PD-1 blocker. A second Phase III trial has just started accrual in
advanced stage NSCLC PD-1 positive patients in first-line setting
randomized to 3 mg/kg nivolumab every 2 week versus investiga-
tor choice chemotherapy. It is anticipated that 330 patients will be
accrued to the study with a reporting date in 2017.
Merck also announced the result of phase Ib trial with a 24%
immune-related response (IRRC), median OS was under a year
and with minimal toxicity (49). Interestingly, 6/9 patients who
met the IRRC had high levels of PDL-1, suggesting that this could
be a predictor of response and survival. There are also six ongoing
Phase I and Phase II studies involving PDL-1 blocking antibodies
(MPDL3280A) in NSCLC.
SUMMARY
Targeting the immune system as a viable strategy for the treatment
of lung cancer was until very recently not felt to be viable. Lung
cancer historically was never felt to be a cancer histology that would
lend itself to immune manipulation; however, we are now in an era
of increased understanding of the complexity of tumor-immune
interactions, which has facilitated over the past 5 years an increased
interest and application of immune therapeutic strategies. The
use of lung cancer directed vaccines and immune checkpoint
inhibitors are driving these activities, however, in the future, it
remains to be seen if tumor microenvironment cellular popula-
tions such as Tregs, myeloid derived suppressor cells (MDSC),
tumor-associated macrophages, or soluble tumor immunosup-
pressive mediators such as indoleamine 2,3-dioxygenase (IDO),
arginase, IL-6, IL-10, and other cytokines/chemokines will also
be able to be targeted. Further, oncolytic viruses armed with
immune stimulating constructs or in combination with immune
checkpoint inhibitors, adoptive cellular therapies remain relatively
untested in the clinic and are attractive to consider.
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